Dr. DeMichele is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 South, Perelman Center for Advanced Medicine, University of Pennsylvania
3400 Civic Center Blvd
Philadelphia, PA 19104Phone+1 215-349-5730Fax+1 215-615-3349
Education & Training
- University of Pennsylvania, School of MedicineM.S.C.E., Clinical Epidemiology, 2001
- University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1995 - 1998
- University of Pennsylvania Health SystemResidency, Internal Medicine, 1992 - 1994
- University of Pennsylvania Health SystemInternship, Internal Medicine, 1991 - 1992
- Washington University in St. Louis School of MedicineClass of 1991
- Brown UniversityB.A., Biochemistry, 1983 - 1987
Certifications & Licensure![](https://directory.doximity.com/assets/icons/icon-help-e9f0b148a1e6d1f037dde9f26f025c36bd7c99fd4fe31fd76792996fa2aa5e66.svg)
- PA State Medical License 1991 - 2024
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Advancing Innovation Award (DeMichele, ISPY/TRANSCEND Team Team Co-Investigator) caBIG®, 2010
- Recipient, FOCUS Award for Research in Women's Health Doris Duke Charitable Foundation, 2007
- Join now to see all
Clinical Trials
- Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy Start of enrollment: 2006 Jun 01
- Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer Start of enrollment: 2007 May 01
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.Hope S Rugo, Mike Campbell, Christina Yau, A Jo Chien, Anne M Wallace
Breast Cancer Research and Treatment. 2025-02-01 - Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C.Mark H O'Hara, Opeyemi Jegede, Mark A Dickson, Angela M DeMichele, Richard Piekarz
Clinical Cancer Research. 2025-01-06 - Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-TargetedF-Fluorthanatrace PET in Breast Cancer.Anthony J Young, Austin R Pantel, Mahsa Kiani, Robert K Doot, Sina Bagheri
Journal of Nuclear Medicine. 2024-12-03
Journal Articles
- Distinct Microbial Signatures Associated with Different Breast Cancer TypesAngela M. DeMichele, Michael D. Feldman, Frontiers in Neurology
- Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast CancerAustin D Williams, Amy S Clark, Paul J Zhang, Julia Tchou, Bruce L Levine, Jennifer M Matro, Laurence J Cooper, Alycia So, Lynn M Schuchter, Carl H June, Angela M DeMi..., Clinical Cancer Research
- A randomized trial of electro-accupuncture for arthralgia related to aromatase inhibitor useMao JJ, Xie SX, Farrar JT, Stricker CT, Bowman MA, Bruner D, DeMichele A, European Journal of Cancer, 1/1/2014
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- A Phase II Trial of the CDK 4/6 Inhibitor PD0332991 in Advanced Breast Cancer.DeMichele A, Clark A, Tan KS, Heitjan D, Randolph S, Christensen J, Gallagher M, Lal P, Feldman M, Zhang P, Domchek S, Gogineni K, Keefe S, Rosen M, Fox K, O'Dwyer P, American Society of Clinical Oncology, 1/1/2013
Lectures
- "Neoadjvuant Therapy as a Mechanism for Drug Approval"San Francisco, CA - 1/1/2014
- "San Antonio Update 2013"Morristown, NJ - 1/1/2014
- "Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL"Philadelphia, PA - 1/1/2014
- Join now to see all
Press Mentions
- ‘Alarming Disparities’ in Cancer Trends and Shift to Women, Younger AdultsJanuary 17th, 2025
- Second Generation of I-SPY 2 TRIAL Design Is Driving the "Precise" in Precision MedicineSeptember 16th, 2024
- Two Penn Medicine Abramson Cancer Center Faculty Members Receive Top ASCO AwardsMay 23rd, 2023
- Join now to see all
Grant Support
- Molecular &Genetic Determinants Of Outcome In Breast CancerNational Cancer Institute2007–2008
- Molecular &Genetic Determinants Of Outcome In Breast CANational Cancer Institute2004–2006
- Age, Cell Cycle Markers And Breast Cancer OutcomesNational Cancer Institute1999–2004
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: